Clinical Trial Update: IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for IMCY-0141 in multiple sclerosis (relapsing-remitting) spanning Phase 1 and Phase 2 with safety and efficacy endpoints under the ISEMIS…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• IMCY-0141

Snippet

Sponsor: Imcyse SA | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 1, Phase 2 | Status: UNKNOWN